Pituitary Gland Thyrotoxicosis Adrenal Gland Thyroid/Parathyroid Bone Health Skin + Heart $100 $100 $100 $100 $100 $200 $200 $200 $200 $200 $300 $300 $300 $300 $300 $400 $400 $400 $400 $400 $500 $500 $500 $500 $500

Pituitary $500-64 year-old male being treated for metastatic melanoma

What is Ipilimumab-induced autoimmune hypophysitis?

Autoimmune Hypophysitis (AH) A new and defined clinical entity occurring as a side effect of ipilimumab, a monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4 (CTLA-4) Presents insidiously and have life-threatening complications related to hypocortisolism, hence a high index of clinical suspicion must be exerted High doses of steroids show radiographic resolution and variable improvement in pituitary hormone function Ipilimumab should continue to be prescribed as treatment for metastatic malignancies; however, close clinical observation of progress must be maintained. Further studies are required to determine the safety of continuing therapy with ipilimumab in patients who have developed AH while on treatment. Ipilimumab-induced hypophysitis is a common side-effect with frequent hormonal deficiencies at diagnosis. Usually, hormonal deficiencies improved, except for corticotroph function. Patients receiving these immunomodulatory therapies should be closely monitored especially by systematic baseline hormone measurements after the third infusion and remain at a risk of adrenal insufficiency in the long-term. Eur J Endocrinol 2015;172:195–204

Ipilimumab-Induced Autoimmune Hypophysitis Pre High Dose Steroids Post High Dose Steroids

Ipilimumab-Induced Autoimmune Hypophysitis